CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has entered into a purchase agreement to acquire a commercial-scale radiopharmaceutical manufacturing facility located in Denton, Texas. Molecular Insight is acquiring the facility from NeoRx Manufacturing Group, Inc., a wholly owned subsidiary of Poniard Pharmaceuticals, Inc., for a cost of three million dollars.
